The data are crucial to Otsuka’s bid to get a full approval for Voyxact, as rival Vera's atacicept awaits a July 7 decision.
July 2, 2026 10:50 AM EDT
R&DFDA+
Otsuka reports long-term kidney data key to Voyxact's bid for full approval
Max Gelman
Otsuka on Thursday reported new long-term data that it hopes will convert an accelerated approval to a full green light in kidney disease.
Otsuka's Voyxact preserved kidney function over 12 months in IgA nephropathy patients, new eGFR data show, as the company pursues…
Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s…
Otsuka’s Voyxact slowed the loss of kidney function after one year in patients with a chronic autoimmune kidney disease, but the…
Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression…
Amgen has asked the FDA to review evidence that its drug Tavneos (avacopan), which treats a rare form of vasculitis, is worth…
Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial.
Otsuka Reports Positive Phase 3 VISIONARY Two-Year eGFR Results Demonstrating VOYXACT® (sibeprenlimab-szsi) Prevented Progression to Kidney Failure and Improved Kidney Function in IgA Nephropathy (IgAN)
Abivax rallies 36% as trial data ease safety fears over obefazimod
FDA approves Lumvoa for thyroid eye disease
Viridian may have edge over Amgen in eye drug showdown, analysts argue
